Antifungal susceptibility testing: Practical aspects and current challenges

Clinical Microbiology Reviews

Volumn 14, Issue 4, 2001, Pages 643-658

  Rex, J H ^a   Pfaller, M A ^a   Walsh, T J ^a   Chaturvedi, V ^a   Espinel Ingroff, A ^a   Ghannoum, M A ^a   Gosey, L L ^a   Odds, F C ^a   Rinaldi, M G ^a   Sheehan, D J ^a   Warnock, D W ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AGAR; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; DYE; ERGOSTEROL; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; POSACONAZOLE; RAVUCONAZOLE; SULFONIC ACID DERIVATIVE; TERBINAFINE; VORICONAZOLE;

AREA UNDER THE CURVE; ASPERGILLUS; CANDIDA; COLONY FORMING UNIT; COLORIMETRY; CRYPTOCOCCUS NEOFORMANS; DERMATOPHYTE; DILUTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; LABORATORY TEST; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; MOULD; MYCOSIS; NONHUMAN; PHARMACODYNAMICS; REVIEW; SPECTROPHOTOMETRY; TURBIDITY;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES;

ASPERGILLUS; CANDIDA; FILOBASIDIELLA NEOFORMANS; FUNGI;

EID: 0034758558     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/CMR.14.4.643-658.2001     Document Type: Review

References (233)

1. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection
2. Applications of flow cytometry to clinical microbiology
3. Microbroth antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: An eight-center collaborative study
4. Pharmacokinetics and pharmacodynamics of outpatient intravenous antimicrobial therapy
5. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model
6. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model
7. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model
8. New agents for treatment of systemic fungal infections
9. Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis
10. Quantitation of ergosterol content: Novel method for determination of fluconazole susceptibility of Candida albicans
11. Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and vivo outcome after fluconazole treatment in a murine model of invasive candidiasis
12. Fluconazole disk diffusion procedure for determining susceptibility of Candida species
13. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents
14. Itraconazole in experimental pulmonary aspergillosis: Comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole plasma concentrations
15. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature
16. Standardization of a hyphal inoculum of aspergilli for amphotericin B susceptibility testing
17. A pharmacologic guide to the clinical use of amphotericin B
18. Pharmacokinetics of fluconazole in pediatric patients
19. Yeast in blood cultures: Evaluation of factors influencing outcome
20. A comparison of dynamic characteristics of fluconazole, itraconazole, and amphotericin B against Cryptococcus neoformans using time-kill methodology
21. Pharmacodynamics of fluconazole, itraconazole, and amphotericin B against Candida albicans
22. Evaluation of the susceptibility of dermatophytes to antifungal drugs: A new technique
23. Fluconazole susceptibilities of bloodstream Candida sp. isolates as determined by National Committee for Clinical Laboratory Standards method M27-A and two other methods
24. Clinical response to ketoconazole of HIV-related oral candidosis is predicted by Odds' relative growth method of susceptibility testing
25. Unresponsive HIV-related oro-oesophageal candidosis - An evaluation of two new in-vitro azole susceptibility tests
26. Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole
27. Evaluation of a capacitance method for direct antifungal susceptibility testing of yeasts in positive blood cultures
28. Antifungal susceptibility testing using the E test: Comparison with the broth macrodilution technique
29. Comparison of a photometric method with standardized methods of antifungal susceptibility testing of yeasts
30. Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: Results from a multicenter prospective study of candidemia
31. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing
32. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
33. Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp.
34. Decreased fluconazole susceptibility of a relapse Cryptococcus neoformans isolate after fluconazole treatment
35. In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis
36. Evaluation of the E test for fluconazole susceptibility testing of Candida albicans isolates from oropharyngeal candidiasis
37. Comparative evaluation of FUNGITEST and broth microdilution methods for antifungal drug susceptibility testing of Candida species and Cryptococcus neoformans
38. Comparison of a new commercial colorimetric microdilution method with a standard method for in-vitro susceptibility testing of Candida spp. and Cryptococcus neoformans
39. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: A double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day
40. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection
41. Itraconazole resistance in Aspergillus fumigatus
42. Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B
43. Incidence of polyene-resistant yeasts recovered from clinical specimens
44. In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis
45. Evaluation of five commercial antifungal susceptibility testing systems
46. In vitro pharmacodynamic properties of MK-099I determined by time-kill methods
47. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans
48. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida spp.
49. Comparison of in vitro activities of the new triazole Posaconazole and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
50. Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole
51. In vitro activities of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
52. Standardization of antifungal susceptibility testing and clinical relevance
53. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi
54. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi
55. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests
56. Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using casitone agar and solidified RPMI 1640 medium with 2% glucose
57. Multicenter comparison of the Sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory Standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms
58. Comparison of two alternative microdilution procedures with the National Committee for Clinical Laboratory Standards Reference Macrodilution Method M27-P for in vitro testing of fluconazole-resistant and -susceptible isolates of Candida albicans
59. In vitro susceptibility methods and clinical implications of antifungal resistance
60. In vitro susceptibility pattern of Candida lusitaniae and evaluation of the Etest method
61. Amphotericin B susceptibility testing of Candida lusitaniae isolates by flow cytofluorometry: Comparison with the Etest and the NCCLS broth macrodilution method
62. Evolving role of flucytosine in immunocompromised patients - New insights into safety, pharmacokinetics, and antifungal therapy
63. Neutral red assay in minimum fungicidal concentrations of antifungal agents
64. Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method
65. Susceptibility testing of Cryptococcus neoformans: A microdilution technique
66. Susceptibility testing of fungi: Current status of the correlation of in vitro data with clinical outcome
67. Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance
68. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole
69. Treatment of Candida albicans fungaemia with fluconazole
70. Rapid determination of antifungal activity by flow cytometry
71. LY303366 exhibits rapid and potent fungicidal activity in flow cytometric assays of yeast viability
72. Antifungal pharmacodynamics: Concentration-effect relationships in vitro and in vivo
73. Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development
74. Comparison of in vitro antifungal susceptibilities of conidia and hyphae of filamentous fungi
75. Collaborative evaluation in seven laboratories of a standardized micromethod for yeast susceptibility testing
76. In vitro pharmacodynamic characteristics of nystatin including time-kill and postantifungal effect
77. Comparison of a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenyl-amino) carbonyl]-2H-tetrazolium hydroxide (XTT) colorimetric method with the Standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast isolates for susceptibility to antifungal agents
78. The use of flow cytometry as a tool for monitoring filament formation of fungi
79. Flucytosine monotherapy for cryptococcosis
80. Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: Studies of interpatient variations in concentrations
81. Isolation and characterization of a pigmentless-conidium mutant of Aspergillus fumigatus with altered conidial surface and reduced virulence
82. Colormetric susceptibility testing for Aspergillus fumigatus: Comparison of menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide and Alamar Blue tests
83. Fluconazole susceptibility testing of Cryptococcus neoformans: Comparison of two broth microdilution methods and clinical correlates among isolates from Ugandan AIDS patients
84. An evaluation of the in vitro activity of terbinafine
85. Antifungal susceptibility testing of dermatophytes: Establishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates
86. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection
87. Rapid susceptibility testing of Candida albicans by flow cytometry
88. Influence of test conditions on antifungal time-kill curve results: Proposal for standardized methods
89. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans
90. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans
91. Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium
92. Rapid detection of susceptibility to fluconazole in Candida species by a bioluminescence assay of intracellular ATP
93. Characterization of echinocandin-resistant mutants of Candida albicans: Genetic, biochemical, and virulence studies
94. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis
95. Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining
96. Amphotericin B resistance testing of Candida spp.: A comparison of methods
97. Safety, tolerance, and pharmacokinetics of fluconazole in children with neoplastic diseases
98. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole
99. Oral therapy of common superficial fungal infections of the skin
100. In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods
101. Assessment of the effect of amphotericin B on the vitality of Candida albicans
102. In vitro susceptibility of Cryptococcus neoformans isolates to five antifungal drugs using a colorimetric system and the reference microbroth method
103. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis
104. Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans
105. Evaluation of a colorimetric method for detecting amphotericin B-resistant Candida isolates
106. Lot-to-lot variability of antibiotic medium 3 when used for susceptibility testing of Candida isolates to amphotericin B
107. Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: Performance of three different media assessed by using E-Test and National Committee for Clinical Laboratory Standards M27-A methodologies
108. In vitro susceptibility of dermatophytes to antifungal drugs: A comparison of two methods
109. In-vitro isolation and antifungal susceptibility of amphotericin B-resistant mutants of Aspergillus fumigatus
110. Comparative study of susceptibilities of germinated and ungerminated conidia of Aspergillus fumigatus to various antifungal agents
111. Reduced susceptibility in laboratory-selected mutants of Aspergillus fumigatus to itraconazole due to decreased intracellular accumulation of the antifungal agent
112. The trailing endpoint phenotype in antifungal susceptibility testing is pH-dependent
113. Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain
114. In vitro evaluation of terbinafine and itraconazole against dematiaceous fungi
115. A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion
116. Comparison of NCCLS and 3-(4,5-dimethyl-2-thiazyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method
117. Isolation and characterization of a polyene-resistant variant of Candida tropicalis
118. Azole resistance among oral Candida species isolates from AIDS patients under ketoconazole exposure
119. Tinea capitis dermatophytes: Susceptibility to antifungal drugs tested in vitro and in vivo
120. Antifungal drug resistance in Aspergillus
121. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo
122. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia
123. The changing face of candidemia: Emergence of non-C. albicans species and antifungal resistance
124. Antimicrobial susceptibility testing of dermatophytes - Comparison of the agar macrodilution and broth microdilution tests
125. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia
126. Optimal growth conditions for the determination of the antifungal susceptibility of three species of dermatophytes with the use of a microdilution method
127. Correlation of in vitro and in vivo susceptibility of Candida albicans to amphotericin B and natamycin
128. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models
129. Antifungal susceptibility testing of yeasts: Evaluation of technical variables for test automation
130. Amphotericin B susceptibility testing of Candida species by flow cytometry
131. Comparative evaluation of microdilution and chromogenic agar screening for determining fluconazole susceptibility of Candida albicans
132. A simple method for detecting fluconazole resistant yeasts with chromogenic agar
133. Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virus-infected children: In vitro and clinical correlations
134. Drug resistance in Cryptococcus neoformans
135. Evaluation of a flow cytofluorometric method for rapid determination of amphotericin B susceptibility of yeast isolates
136. Improved detection of amphotericin B-resistant isolates of Candida lusitaniae by Etest
137. Clinical evaluation of the ASTY colorimetric microdilution panel for antifungal susceptibility testing
138. Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B
139. Multisite reproducibility of the Etest MIC method for antifungal susceptibility testing of yeast isolates
140. Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazole D070
141. Multisite reproducibility of MIC results by the Sensititre (R) YeastOne colorimetric antifungal susceptibility panel
142. Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media
143. In vitro susceptibility testing of filamentous fungi: Comparison of Etest and reference microdilution methods for determining itraconazole MICs
144. Antifungal susceptibility testing: Technical advances and potential clinical applications
145. Amphotericin B synergy testing by the FCST
146. Antibiotic susceptibility testing by flow cytometry
147. Antibiotic susceptibility testing of Candida albicans by flow cytometry
148. Ketoconazole susceptibility of yeasts by the FCST method
149. Commercial systems for fluconazole susceptibility testing of yeasts: Comparison with the broth microdilution method
150. Amphotericin B-resistant Cryptococcus neoformans in a patient with AIDS
151. Amphotericin B-resistant yeast infection in severely immunocompromised patients
152. Preliminary evaluation of a semisolid agar antifungal susceptibility test for yeasts and molds
153. Comparison study of broth macrodilution and microdilution antifungal susceptibility tests for the filamentous fungi
154. Effects of incubation temperature, inoculum size, and time of reading on broth microdilution susceptibility test results for amphotericin B against Fusarium
155. Comparison of a colorimetric microdilution method and the NCCLS macrodilution method for antifungal susceptibility testing of yeasts
156. Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients
157. Multicenter evaluation of ATB fungus: A standardized micromethod for yeast susceptibility testing
158. Flow cytometry antifungal susceptibility testing of pathogenic yeasts other than Candida albicans and comparison with the NCCLS broth microdilution test
159. Rapid flow cytometric susceptibility testing of Candida albicans
160. Susceptibility testing of pathogenic fungi with itraconazole: A process analysis of test variables
161. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazoleresistant Candida in human immunodeficiency virus-infected patients
162. Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method
163. Detection of amphotericin B-resistant Candida isolates in a broth-based system
164. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis
165. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections
166. Antifungal susceptibility testing
167. Determination of antifungal MICs by a rapid susceptibility assay
168. In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy
169. Timed-kill curves for Cryptococcus neoformans isolated from patients with AIDS
170. Update on invasive candidiasis
171. Influence of shaking on antifungal susceptibility testing of Cryptococcus neoformans: A comparison of the NCCLS standard M27A medium, buffered yeast nitrogen base, and RPMI-2% glucose
172. Defining conditions for microbroth antifungal susceptibility tests: Influence of RPMI and RPMI-2% glucose on the selection of endpoint criteria
173. Improved medium for fluconazole susceptibility testing of Candida albicans
174. Correlation of in vitro susceptibility test results with in vivo response: A study of azole therapy in AIDS patients
175. In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts
176. Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients
177. Detection of fluconazole-resistant Candida strains by a disc diffusion screening test
178. Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life
179. An evalution of seven methods of in vitro susceptibility testing of clinical yeast isolates against fluconazole
180. Pharmcokinetics of fluconazole in immune-compromised children with leukemia or other hematologic disease
181. Amphotericin B tolerance: A characteristic of Candida parapsilosis not shared by other Candida species
182. Comparison of broth macrodilution, broth microdilution, and Etest antifungal susceptibility tests for fluconazole
183. Acetate-mediated growth inhibition in sterol 14 alpha-demethylation-deficient cells of Candida albicans
184. Estimation of minimum sterol 14 alpha-demethylation-inhibitory concentration of azoles in Candida yeasts using acetate-mediated growth inhibition: Potential utility in susceptibility testing
185. Comparative study of agar diffusion test and the NCCLS macrobroth method for in vitro susceptibility testing of Candida spp.
186. Emergence of resistance to amphotericin B during therapy for Candida glabrata infection in an immunocompetent host
187. Resistance to amphoterricin B: Emerging clinical and microbiological patterns
188. Ketoconazole and itraconazole susceptibility of Candida albicans isolates from patients infected with HIV
189. Correlation of in vitro susceptibility test results with in vivo response: Flucytosine therapy in a systemic candidiasis model
190. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole
191. Comparative evaluation of Fungitest (R), Neo-Sensitabs (R) and M27T-NCCLS broth microdilution methods for antifungal drug susceptibility testing of Candida species and Cryptococcus neoformans
192. Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of molds
193. Innovative endpoint determination system for antifungal susceptibility testing of yeasts
194. Effects of incubation time and buffer concentration on in vitro activities of antifungal agents against Candida albicans
195. Aspergillus versicolor as cause of onychomycosis: Report of 12 cases and susceptibility testing to antifungal drugs
196. Antifungal drug resistance in pathogenic fungi
197. Disk diffusion susceptibility testing of dermatophytes with allylamines
198. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis
199. Experimental Trichosporon infection in persistently granulocytopenic rabbits: Implications for pathogenesis, diagnosis, and treatment of an emerging opportunistic mycosis
200. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B
201. Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii
202. Clinical, microbiological, and experimental animal studies of Candida lipolytica
203. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: Enhanced ability to detect amphotericin B-resistant Candida isolates
204. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans
205. Rapid susceptibility testing of fungi by flow cytometry using vital staining
206. Hypothesis on the mechanisms of resistance to fluconazole in Histoplasma capsulatum
207. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance
208. Susceptibility testing of Candida species: Comparison of NCCLS microdilution method with Fungitest (R)
209. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: The role of antifungal susceptibility testing
210. Evaluation of the fungitest kit by using strains from human immunodeficiency virus-infected patients: Study of azole drug susceptibility
211. Colorimetric MTT assessment of antifungal activity of D0870 against fluconazole-resistant Candida albicans
212. Modified agar dilution susceptibility testing method for determining in vitro activities of antifungal agents, including azole compounds